Key Clinical Trial Developments Signals for argenx (NASDAQ:ARGX)

  • About 15.9% was the premarket drop in argenx (NASDAQ:ARGX) to USD 781.00 on October 8, 2026, after an independent committee recommended stopping the Phase 3 UNITY study in Sjögren's disease for futility.
  • USD 1.516 billion of second quarter 2026 product net sales, representing an increase of 60% against the year-ago period and all from VYVGART, is a commercial base at argenx (NASDAQ:ARGX) that does not depend on Sjögren's disease.
  • USD 5.2 billion of cash and current financial Assets at June 30, 2026 gives argenx (NASDAQ:ARGX) funding for its other late stage programs, including empasiprubart data guided for the fourth quarter of 2026.
  • October 22, 2026 is the scheduled date for argenx (NASDAQ:ARGX) third quarter results, the next chance to hear management discuss the UNITY outcome and intends for its remaining pipeline.

Clinical Trial Developments: Outlook Implications for argenx (NASDAQ:ARGX)

According to In a release issued at 7:00 a.m. CET on October 8, 2026 (1:00 a.m. ET), argenx, it will discontinue the Phase 3 UNITY study of efgartigimod SC in adults with moderate to severe Sjögren's disease. According to The company, safety was consistent with the known profile and no new signals appeared. Patient numbers were not disclosed. An independent data monitoring committee recommended stopping after an interim analysis for futility, meaning the study could not meet its primary endpoint. According to Chief Medical Officer Luc Truyen, the company was disappointed. As of the premarket quote on October 8, 2026, published market data indicated argenx (NASDAQ:ARGX) down about 15.9% at USD 781.00, while an earlier premarket print indicated a smaller fall.

Clinical Trial Developments: Key Business Impact on argenx (NASDAQ:ARGX)

UNITY randomized patients 1:1 to weekly efgartigimod SC or placebo, with the change in clinESSDAI disease activity score at Week 48 as the primary endpoint. A futility stop means interim data suggested the effect would not reach significance, so it ends a potential new indication. Investors price pipeline breadth, which is why a failed indication can move argenx (NASDAQ:ARGX) sharply even when current sales are strong. Efgartigimod lowers circulating IgG antibodies, and Sjögren's patients in the trial were anti-Ro/SSA positive, so the idea was to reduce autoantibody driven disease. It does not change approved uses such as generalized myasthenia gravis. UNITY toplines had been guided for the second half of 2027.

Risks From Clinical Trial Developments for argenx (NASDAQ:ARGX)

The main risk is concentration: all USD 2.813 billion of first half 2026 product sales came from VYVGART, so further trial setbacks matter. Offsetting data came on August 17, 2026, when ALKIVIA in myositis met its primary endpoint in the combined population, though dermatomyositis alone was not significant. Premarket prices can reverse by the open, and no analyst reaction was found at the time of writing. The company has not disclosed why efgartigimod missed, and a full analysis will follow database lock. Upcoming dates include third quarter results on October 22, 2026, EMPASSION topline data for empasiprubart in the fourth quarter of 2026 and ADVANCE-NEXT in primary immune thrombocytopenia in the first half of 2027.

argenx (NASDAQ:ARGX) After the Latest Clinical Trial Developments Update

The company reported strong second quarter sales, USD 5.2 billion of cash and positive myositis data in August, so the business is not defined by this one result. The drop in argenx (NASDAQ:ARGX) reflects a futility stop of the Phase 3 UNITY study in Sjögren's disease, announced on October 8, 2026, which removes a late stage indication from the pipeline. Premarket moves are provisional. Key open items are the full UNITY analysis, third quarter results on October 22, 2026, and empasiprubart data in the fourth quarter.